| Organotropism: new insights into molecular mechanisms of breast cancer metastasis |
30 |
| Role of nonresolving inflammation in hepatocellular carcinoma development and progression |
28 |
| Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis |
28 |
| Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 |
26 |
| Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway |
23 |
| Cardiotoxicity with vascular endothelial growth factor inhibitor therapy |
22 |
| Tumor evolution and chemoresistance in ovarian cancer |
20 |
| CRISPR/Cas9 - An evolving biological tool kit for cancer biology and oncology |
17 |
| A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types |
13 |
| Artificial intelligence for precision oncology: beyond patient stratification |
12 |
| Accumulation of genetic and epigenetic alterations in normal cells and cancer risk |
12 |
| Liquid biopsy: one cell at a time |
10 |
| Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers |
9 |
| Cancer prevention and screening: the next step in the era of precision medicine |
9 |
| Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways |
9 |
| Rapid MALDI mass spectrometry imaging for surgical pathology |
9 |
| Emerging role of precision medicine in biliary tract cancers |
8 |
| Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology |
8 |
| Universal cancer screening: revolutionary, rational, and realizable |
8 |
| Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients |
8 |
| Pan-cancer analysis connects tumor matrisome to immune response |
8 |
| Liquid biopsy for pediatric central nervous system tumors |
8 |
| Propranolol exhibits activity against hemangiomas independent of beta blockade |
7 |
| Immunogenetics of glioblastoma: the future of personalized patient management |
6 |
| A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer |
6 |
| Interaction of tumor cells and astrocytes promotes breast cancer brain metastases through TGF-beta 2/ANGPTL4 axes |
6 |
| SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response |
6 |
| RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level |
6 |
| Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma |
6 |
| Immunotherapeutic advances in gastrointestinal malignancies |
5 |
| Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip |
5 |
| Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types |
5 |
| Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity |
5 |
| Superhydrophobic lab-on-chip measures secretome protonation state and provides a personalized risk assessment of sporadic tumour |
5 |
| Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer |
5 |
| Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC |
5 |
| Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer |
5 |
| Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response |
5 |
| Vasodilator-stimulated phosphoprotein promotes liver metastasis of gastrointestinal cancer by activating a beta 1-integrin-FAK-YAP1/TAZ signaling pathway |
4 |
| Precision oncology of lung cancer: genetic and genomic differences in Chinese populationnn |
4 |
| Enzyme-mediated depletion of L-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth |
4 |
| Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy |
4 |
| Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data |
3 |
| Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology |
3 |
| The PGC-1/ERR network and its role in precision oncology |
3 |
| Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution |
3 |
| Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma |
3 |
| A plasma protein derived TGF beta signature is a prognostic indicator in triple negative breast cancer |
2 |
| Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations |
2 |
| A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia |
2 |
